AwesomeCapital
Search This Blog
Wednesday, June 10, 2026
FDA accepts Takeda supplemental BLA for intravenous Entyvio in pediatric ulcerative colitis, Crohn’s
FDA accepts Takeda supplemental BLA for intravenous Entyvio in pediatric ulcerative colitis and Crohn’s disease
PDUFA target action date
for the
Entyvio pediatric sBLA
is scheduled in the
first quarter of 2027
.
https://finviz.com/stock?t=TAK&p=d
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.